<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: STAT3 is a transcription factor that is constitutively activated in some <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It seems to play crucial roles in cell proliferation and survival, <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-promoting <z:mp ids='MP_0001845'>inflammation</z:mp>, and suppression of antitumor host immune response in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment </plain></SENT>
<SENT sid="2" pm="."><plain>Although the STAT3 signaling pathway is a potential drug target, clinical, pathologic, molecular, or prognostic features of STAT3-activated <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> remain uncertain </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: Utilizing a database of 724 colon and <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> cases, we evaluated phosphorylated STAT3 (p-STAT3) expression by immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>The Cox proportional hazards model was used to compute mortality HR, adjusting for clinical, pathologic, and molecular features, including microsatellite instability (MSI), the CpG island methylator phenotype (CIMP), LINE-1 methylation, 18q LOH, TP53 (p53), CTNNB1 (Î²-catenin), JC virus T-antigen, and KRAS, BRAF, and PIK3CA mutations </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Among the 724 tumors, 131 (18%) showed high-level p-STAT3 expression (p-STAT3-high), 244 (34%) showed low-level expression (p-STAT3-low), and the remaining 349 (48%) were negative for p-STAT3 </plain></SENT>
<SENT sid="6" pm="."><plain>p-STAT3 overexpression was associated with significantly higher <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific mortality [log-rank P = 0.0020; univariate HR (p-STAT3-high vs. p-STAT3-negative): 1.85, 95% CI: 1.30-2.63, P(trend) = 0.0005; multivariate HR: 1.61, 95% CI: 1.11-2.34, P(trend) = 0.015] </plain></SENT>
<SENT sid="7" pm="."><plain>p-STAT3 expression was positively associated with peritumoral lymphocytic reaction (multivariate OR: 3.23; 95% CI: 1.89-5.53, P &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>p-STAT3 expression was not associated with MSI, CIMP, or LINE-1 hypomethylation </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: STAT3 activation in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is associated with adverse clinical outcome, supporting its potential roles as a prognostic biomarker and a chemoprevention and/or therapeutic target </plain></SENT>
</text></document>